In today's post, LaMattina answers:
It would seem to me that we’re generally looking at the major CROs as being the ones that can scale to address this kind of research. Is that safe to say?
John: I would say that, yes. But it depends on the disease. So, for example, let’s talk about kidney cancer as an example. There are drugs out there to treat kidney cancer, but they are not 100% successful. There is occasionally a relapse on these therapies. So, you could envision a company coming up with a new drug to treat kidney cancer and you’ve got to give it a comparison to a sustained therapy. But for a study like that, you don’t have to run it for years. Depending on the nature of the patient population you may have to run it for six months to a year. And you wouldn’t need tens of thousands of patients. You would only need a small number of patients.
So, a lot of this, Marc, would really depend upon the nature of the trial and the nature of the disease and what you’re trying to prove. I wouldn’t say that it all would go to the large players. There is room, I think, for everybody depending on your expertise, capabilities and what you can bring to the company that is sponsoring the clinical trial.
Download the rest of John's podcast here.
John LaMattina will be the moderator for the Wall Street State of the Industry Address: Mergers
& Acquisitions in the Industry — Near Term Solution to a Long Term Problem? featuring panelists including Colin Shannon, President, CEO and Director, PRA International; Michael Martorelli, Director, Fairmount Partners; Eric Coldwell, Managing Director, Robert W. Baird & Co.; and Douglas Tsao, MPH, U.S. Specialty Pharmaceuticals & CROs, Barclays Equity Research. Would you like to join John for this panel at Partnerships in Clinical Trials this coming March 30-April 2, 2014? As a reader of this blog, when you register to join us and mention code XP1900BLOG, you're eligible to save $100 off the current rate!